A pre-clinical stage pharmaceutical company in Roskilde, Denmark.
Biograil develops BIONDD®, working to transform injectable medicines into convenient oral capsules.

Investors
In November 2026 Biograil closed a EUR 20 million round backed by Verve Ventures and Megatrend Invest. HTGF, which led the 2019 seed syndicate, takes part through its HTGF Opportunity fund. The funds go to preparing Phase 1 clinical testing of BIONDD®, including non-clinical GLP studies and a GMP manufacturing process. A larger financing is expected in 2027.
→Contact investor relationsSenior or Principal Scientist, Analytical Development & CMC
Join the Pharmaceutical Research organization and own analytical development and CMC for the BIONDD™ oral delivery platform, across drug substance, drug product and combination products. Reports to the Senior Director Pharmaceutical Research.
- LocationLangebjerg 1, 4000 Roskilde, Denmark
- Deadline1 December 2026
- You bringA master's or PhD in a related field and 5+ years of biotherapeutic analytical experience. Oral drug product experience is an advantage.
- QuestionsAnne Tungelund Larsen, Senior Director Pharmaceutical Research, atl@biograil.com
Contact
- CompanyBiograil ApS
- AddressLangebjerg 1, 4000 Roskilde, Denmark
- Emailinfo@biograil.com